Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 4

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
151,715)

FOR THE PERIOD FROM MAY 23, 2024 (INCEPTION)
THROUGH JUNE 30, 2024

    Ordinary Shares  
    Share Subscription  
    Additional Paid-in  
    Accumulated  
    Total Shareholders’ 

    Shares  
    Amount  
    Receivable  
    Capital  
    Deficit  
    Deficit 
  
    Balance — May 23, 2024 (Inception) 
     —  
    $—  
    $—  
    $—  
    $—  
    $— 

    Issuance of ordinary shares (1)(2) 
     9,857,143  
     986  
     —  
     34,014  
     —  
     35,000 

    Net income 
     —  
     —  
     —  
     —  
     (54,931) 
     (54,931)

    Balance – June 30, 2024 
     9,857,143  
    $986  
    $—  
    $34,014  
    $(54,931) 
    $(19,931)

(1)Includes an aggregate of up to 1,285,714 ordinary shares subject
to surrender and forfeiture if the over-allotment option were not exercised in full by the underwriters (Note 5). In February 2025, the
over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).

(2)On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968
ordinary shares to the Company for no consideration, following which the Sponsor held 9,857,143 ordinary shares. All share and per share
data has been retrospectively presented.

The accompanying notes are an integral part of
the unaudited financial statements.

3

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

    Six Months Ended June 30,  
    For the Period from May 23, 2024 (inception) through June 30, 

    2025  
    2024 
  
    Cash Flows from Operating Activities: 

    Net